APA (7th ed.) Citation

NE, S., DL, B., J, B., D, B., C, K., H, M., . . . S, J. (2025). Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: Results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrobial agents and chemotherapy, 69(10), e0164024. https://doi.org/10.1128/aac.01640-24

Chicago Style (17th ed.) Citation

NE, Scangarella-Oman, et al. "Efficacy and in Vitro Activity of Gepotidacin Against Bacterial Uropathogens, Including Drug-resistant Phenotypes, in Females with Uncomplicated Urinary Tract Infections: Results from Two Global, Pivotal, Phase 3 Trials (EAGLE-2 and EAGLE-3)." Antimicrobial Agents and Chemotherapy 69, no. 10 (2025): e0164024. https://doi.org/10.1128/aac.01640-24.

MLA (9th ed.) Citation

NE, Scangarella-Oman, et al. "Efficacy and in Vitro Activity of Gepotidacin Against Bacterial Uropathogens, Including Drug-resistant Phenotypes, in Females with Uncomplicated Urinary Tract Infections: Results from Two Global, Pivotal, Phase 3 Trials (EAGLE-2 and EAGLE-3)." Antimicrobial Agents and Chemotherapy, vol. 69, no. 10, 2025, p. e0164024, https://doi.org/10.1128/aac.01640-24.